(Reuters) – Incyte Corp said on Monday its cream, ruxolitinib, to treat pigmentation disorder vitiligo met the main goal in a late-stage study.
The drugmaker said the data will support U.S. and EU regulatory submissions in the second half of 2021.
(Reporting by Dania Nadeem in Bengaluru; Editing by Devika Syamnath)
